LifeMD (NASDAQ:LFMD) Given New $3.00 Price Target at Lake Street Capital

LifeMD (NASDAQ:LFMD) had its target price lowered by Lake Street Capital from $5.00 to $3.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on the stock. B. Riley Financial began coverage on shares of LifeMD in a research note on Friday, September 11th. They issued a “buy” rating and a $8.00 price objective for the company. Mizuho reduced their target price on shares of LifeMD from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Friday. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of LifeMD in a research report on Thursday, September 17th. Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Finally, BTIG Research lowered their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.14.

LifeMD Trading Up 32.6%

Shares of LFMD stock traded up $0.54 on Friday, reaching $2.19. The company’s stock had a trading volume of 6,142,984 shares, compared to its average volume of 944,039. The stock’s fifty day simple moving average is $2.60 and its 200-day simple moving average is $3.57. LifeMD has a 1 year low of $1.60 and a 1 year high of $5.38. The company has a market capitalization of $105.80 million, a price-to-earnings ratio of -36.58 and a beta of 2.19.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. The company had revenue of $44.63 million for the quarter, compared to analysts’ expectations of $48.84 million. LifeMD had a negative net margin of 0.25% and a negative return on equity of 139.69%. Equities research analysts forecast that LifeMD will post -0.48 earnings per share for the current year.

Hedge Funds Weigh In On LifeMD

Several large investors have recently modified their holdings of the stock. Walleye Capital LLC purchased a new position in shares of LifeMD during the second quarter valued at approximately $1,338,000. Russell Investments Group Ltd. raised its holdings in shares of LifeMD by 5,801.2% in the second quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock worth $1,300,000 after buying an additional 309,436 shares during the period. Bank of America Corp DE purchased a new stake in shares of LifeMD in the second quarter worth approximately $1,078,000. Marshall Wace LLP raised its holdings in shares of LifeMD by 45.1% in the third quarter. Marshall Wace LLP now owns 809,138 shares of the company’s stock worth $2,347,000 after buying an additional 251,664 shares during the period. Finally, State Street Corp lifted its stake in shares of LifeMD by 22.6% during the 2nd quarter. State Street Corp now owns 1,318,784 shares of the company’s stock worth $5,447,000 after acquiring an additional 243,376 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

Latest LifeMD News

Here’s some of the latest news about LFMD:

• Positive Sentiment: LifeMD reported a third-quarter loss of $0.11 per share, narrower than the expected $0.14 loss. Adjusted EBITDA also improved by about $3.1 million sequentially, to a loss of roughly $0.4 million, as the company reduced marketing and other non-clinical expenses. LifeMD Q3 2026 results
• Neutral Sentiment: Lake Street Capital lowered its price target from $5 to $3 but kept a Buy rating; Mizuho cut its target from $7 to $6 and maintained an Outperform rating. The retained positive ratings offer support, though both target reductions reflect more cautious expectations. Analyst rating and price target update
• Negative Sentiment: Revenue was $44.6 million, below analysts’ $48.8 million estimate. LifeMD also forecast fourth-quarter revenue of $46–$49 million, versus consensus of $61.4 million, and full-year 2026 revenue of $188–$191 million, versus $207.6 million expected. The shortfall in guidance may weigh on investor expectations for near-term growth. LifeMD Q3 2026 results and guidance

About LifeMD

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.